By Mill Chart
Last update: May 8, 2024
Take a closer look at ALKERMES PLC (NASDAQ:ALKS), a remarkable value stock uncovered by our stock screener. NASDAQ:ALKS excels in fundamentals and maintains a very reasonable valuation. Let's break it down further.
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:ALKS was assigned a score of 9 for valuation:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:ALKS has achieved a 6:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:ALKS has earned a 7 out of 10:
Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:ALKS boasts a 5 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of ALKS for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
ALKERMES PLC
NASDAQ:ALKS (5/17/2024, 7:00:00 PM)
After market: 24.15 0 (0%)24.15
-0.31 (-1.27%)
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and...
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to...
Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing?
ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...